Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (122,523)	$ (72,694)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash in-process research and development	11,184	0
Stock-based compensation	13,897	8,579
Amortization of debt discount and issuance costs	4,504	0
Depreciation and amortization	2,152	1,418
Amortization of discount on investments	(1,111)	(1,481)
Other non-cash operating activities	240	338
Changes in operating assets and liabilities:
Accounts receivable	(49)	27,000
Inventories	(778)	0
Prepaid expenses and other current assets	(1,179)	(2,903)
Operating lease right of use assets	1,165	(2,938)
Other non-current assets	30	853
Accounts payable	(1,099)	(321)
Accruals and other liabilities	4,052	(914)
Deferred revenue	30,692	(278)
Operating lease liabilities	(1,679)	2,637
Net cash used in operating activities	(60,502)	(40,704)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments	(159,412)	(164,970)
Purchases of property and equipment	(1,113)	(1,459)
Purchase of intangible assets	(118)	0
Proceeds from maturities of investments	132,000	117,000
Proceeds from sale of investments	16,969	0
Net cash used in investing activities	(11,674)	(49,429)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible senior notes	287,500	0
Proceeds from issuance of common stock in connection with offerings, net of commissions and discount	15,581	108,100
Proceeds from the exercise of stock options, common stock warrants and employee stock purchase plan	1,670	480
Payment of capped call transactions	(28,865)	0
Payment of convertible senior notes transaction costs	(9,190)	0
Net settlement of restricted stock awards for employee taxes	(1,512)	(1,148)
Payment of offering costs	(337)	(521)
Net cash provided by financing activities	264,847	106,911
NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	192,671	16,778
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period	171,890	73,986
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period	364,561	90,764
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Issuance of common stock in connection with the Teoxane Agreement	43,400	0
Property and equipment purchases included in accounts payable and accruals	$ 159	$ 1,408